NCT00425035已完成2 期
A Two-part, Multiple Dose Clinical Trial Evaluating the Safety and Effectiveness of ABX-EGF in Patients With Renal Carcinoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 115
- 主要终点
- Part 2, Cohort 1: Efficacy: Tumor response rate (CR or PR) measured at 8 weeks
研究概览
简要总结
Multicenter, 2-part, multiple-dose study designed to evaluate the safety and effectiveness of weekly administration of panitumumab in subjects with renal carcinoma. Part 1 was initiated in 2001 and will not be presented here. Part 2 was designed to examine a dose of 2.5 mg/kg/wk in 2 cohorts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 接受健康志愿者
- 否
入选标准
- •Able to comprehend and sign an IRB approved Informed Cosent Form
- •Male or female 18 years of age or older
- •Female patients who are post menopausal (no menstrual period for a minimum of six months), surgically sterilized, or are using an oral or implanted contraceptive, double barrier birth control, or an IUD and have a negative serum pregnancy test upon entry into this study; or male patients willing to use contraception upon enrollment into this study
- •Pathologic diagnosis of renal cell carcinoma by fine needle aspirate or tissue biopsy
- •Prior nephrectomy
- •Prior Therapy:
- •Cohort 1 only: Previously received and failed one prior biotherapy, defined as IL-2 therapy or interferon-alpha (alone or in combination); Karnosky score of > or = 70%
- •Cohort 2 only: No prior therapy except nephrectomy and fall within the Motzer intermediate group with one or two of the risk factors, as defined in teh Study Design section.
- •Has bi-dimensionally measurable disease
- •Has tumor tissue available for diagnostics (acceptable: biopsy, nephrectomy tissue, fine needle aspirate, or archived tissue that is formalin fixed and paraffin embedded). In cases when a fresh biopsy can be obtained, the biopsy should be divided into two; one half should be formalin fixed, and the other half frozen. Tumor samples must be received at the central laboratory prior to patient regisration.
- •Adequate hematologic data, as follows:
- •ANC > 1.5 x 109/L
- •Platelet count > 100x 109/L
- •Adequate renal function, as follows:
- •1. Creatinine < or = 2.2mg/dL
- •Adequate hepatic function, as follows:
- •Alkaline phosphatase < or = 3x ULN
- •AST < or = 3x ULN
- •ALT < or = 3x ULN
- •Total bilirubin < or = 1.5x ULN
排除标准
- •Brain metastases
- •Cohort 1 only: Hypercalcemia (calcium level outside the upper limit of normal; antihypercalcemic treatment is allowed)
- •Cancer therapy within 30 days of ABX-EGF infusion (hormone therapy is allowed; steroid therapy is only allowed if it is replacement therapy)
- •Use of any investigational drug within 30 days of ABX-EGF infusion
- •Prior treatment with any anti-EGFr agents
- •Left ventricular ejection fraction < 45%, as measured by MUGA Scan
- •Myocardial infarction within one year prior to entering the study
- •Has other cancer that has been active and required treatment within the past 5 years (prior renal cell carcinoma, basal cell carcinoma, or cervical carcinoma in situ are allowed)
- •Pregnant or breast feeding female; male or female of childbearing potential (defined as: post menarche and is biologically capable of becoming pregnant) unwilling to use birth control (as defined in the inclusion criteria) during and for 1 month following treatment
- •Known to be HIV positive
- •History of any chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the Investigator may increase the risks associated with study participation or study drug administration or may interfere with the interpretation of study results
- •Allergy to the ingredients of the study medication or to Staphylococcus Protein A
结局指标
主要结局
Part 2, Cohort 1: Efficacy: Tumor response rate (CR or PR) measured at 8 weeks
Part 2, Cohort 1: Safety: Incidence and severity of AEs
Part 2, Cohort 2: Time to disease progression
次要结局
- Part 2, Cohort 1: Time to disease progression
- Part 2, Cohorts 1 & 2: Survival time
- Part 2, Cohorts 1 & 2: PFS
- Part 2, Cohorts 1 & 2: Best overall response rate
- Part 2, Cohorts 1 & 2: Tumor response rate at Weeks 15, 23, 31, and 39
- Part 2, Cohorts 1 & 2: Duration of response
- Part 2, Cohorts 1 & 2: Percent of patients with progressive disease (measured at 8 weeks following initiation of panitumumab treatment)
- Part 2, Cohorts 1 & 2: Time to CR
- Part 2, Cohorts 1 & 2: Time to response (PR or CR)
研究者
相似试验
已完成
2 期
Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain MedicationBowel DysfunctionConstipationNCT00101998Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)233
已完成
1 期
Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)Obstructive Sleep Apnea (OSA)NCT03882801Merck Sharp & Dohme LLC24
招募中
2 期
A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects with DMEDiabetic Macular Edema (DME)NCT06708260EnnovaBio60
已完成
2 期
A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity StatinsHypercholesteremiaNCT02634151NeuroBo Pharmaceuticals Inc.105
终止
1 期
Study of MK-1972 in Human Immunodeficiency Virus (HIV)-1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy (MK-1972-003)HIV-1 InfectionNCT01353898Merck Sharp & Dohme LLC12